Jump to main content
Jump to site search

Issue 19, 2018
Previous Article Next Article

A cancer specific oxaliplatin-releasing Pt(IV)-prodrug

Author affiliations

Abstract

We prepared a Pt(IV)-prodrug, which under cancer specific conditions (elevated concentration of reactive oxygen species, ROS) releases a DNA-binding drug oxaliplatin as well as ROS-amplifying drugs p-quinone methide and N-alkylferrocenium. Due to the concerted action of these components, an excellent anticancer effect was achieved: IC50 = 0.4 ± 0.1 μM for human ovarian carcinoma A2780 cells. Importantly, the prodrug was found to be 45-fold less toxic to normal cells (HDFa).

Graphical abstract: A cancer specific oxaliplatin-releasing Pt(iv)-prodrug

Back to tab navigation

Supplementary files

Publication details

The article was received on 13 Apr 2018, accepted on 23 Apr 2018 and first published on 23 Apr 2018


Article type: Communication
DOI: 10.1039/C8DT01458B
Citation: Dalton Trans., 2018,47, 6679-6682
  •   Request permissions

    A cancer specific oxaliplatin-releasing Pt(IV)-prodrug

    V. Reshetnikov, A. Arkhypov, P. R. Julakanti and A. Mokhir, Dalton Trans., 2018, 47, 6679
    DOI: 10.1039/C8DT01458B

Search articles by author

Spotlight

Advertisements